Superdisintegrant

Mouth dissolving tablet disintegrates and dissolves rapidly in the saliva, within a few seconds without the need of drinking water or chewing. A mouth dissolving tablet usually dissolves in the oral cavity within 15 seconds to 3 minutes. Almotriptan malate is an anti migraine drug with bitter taste and shows hepatic metabolism.  In the present work, Mouth dissolving tablets of almotriptan malate were prepared by direct compression method using sodium starch glycolate and croscarmellose sodium as superdisintegrant with a view to enhance patient compliance and to avoid gastric dysmotility which is common with migraine drugs and for fast action of drug. The prepared batches of tablets were evaluated for hardness, friability, drug content uniformity, wetting time, water-absorption ratio and in-vitro dispersion time. Short-term stability studies on the promising formulation indicated that there are no significant changes in drug content and disintegration time.

The most popular solid dosage forms are being tablets and capsules; one important drawback of these dosage form for some patients, is the difficulty to swallow. Drinking water plays an important role in swallowing of oral dosage forms. For these reasons tablets that can rapidly dissolve or disintegrate in the oral cavity have attracted a great deal of attention. Mouth dissolving tablets are not only indicated for people who have swallowing difficulties, but also are ideal for active people. The concept of formulating Mouth dissolving tablets containing Metformin Hydrochloride offer a suitable and practical approach in serving the desired objective of faster disintegration and dissolution characteristic with increase bioavailability.

Pulsatile Drug Delivery systems (PDDS) are basically time-controlled drug delivery systems in which the system controls the lag time and drug is released in an immediate or extended fashion. The present study was conducted to develop and evaluate pulsatile release tablets of Rabeprazole sodium for the treatment of peptic ulcers. The compression coated tablets consisted of a core tablet containing drug with superdisintegrant, which was further coated by erodible outer layer consisted of HPMC K15M, ethyl cellulose and Karaya gum. After carrying out preformulation studies, the developed tablets were evaluated for post-compression parameters like weight variation, thickness, hardness, friability, drug content and in-vitro drug release study. The best formulation was selected on the basis of post-compression parameters and was subjected to accelerated stability studies for 1 month. Amongst 6 formulations prepared, C5 produced convincing results with a maximum cumulative drug release of 99.97% in 150 minutes. Also the formulation didn’t show any significant changes during 1 month period of stress testing. By virtue of its release pattern and delivering the drug at the right time, right place and in right amounts, the developed delivery system holds good promises of benefiting the patients suffering from peptic ulcers. The release profile of optimized formulation C5 was close to korsmeyer peppas model. Irrespective of the polymer type and its concentration, the prepared optimized pulsatile tablets showed non fickian (anomalous) release.

The aim of present work was to develop pulsatile release dosage form for chronotherapy of hypertension. Considering the biopharmaceutical, pharmacodynamics reasons of Valsartan and circadian rhythm of hypertension a time controlled rupturable tablet, which allowed the release of Valsartan in time controlled release manner was developed for treating early in the morning surge of blood pressure. Core tablet for formulation were prepared using direct compression technique and evaluated for various parameters like % drug content, hardness, thickness, friability and In-vitro disintegration time. To get desired lag time and release profile to achieve pulsatile delivery tablets were coated with ethyl cellulose: Eudragit L100 (3:1), containing dibutyl phthalate and magnesium stearate. Coated tablet was evaluated for in vitro dissolution study, Drug content and rupture time. Optimization was done by using 32 full factorial design by using conc. of croscarmellose in core and coating level as independent variables and rupture time or lag time as dependent variable. Formulation F-5 was found to optimized formulation containing 5% of superdisintegrant in core tablet and 5 % coating level. From the study it is also concluded that Increase in coating level increases lag time & increase in concentration of superdisintegrant decreases lag time.

Desloratadine is an antagonist at histamine H1 receptors, and an antagonist at all subtypes of the muscarinic acetylcholine receptor. It has a long-lasting effect and in moderate and low doses, does not cause drowsiness because it does not readily enter the central nervous system. The present study is an attempt to formulate and evaluate the fast dissolving tablets of  Desloratadine. Fast dissolving tablets were prepared by direct compression after masking the bitter taste of drug by solid dispersion method with the aid of superdisintegrants. Seven formulations were developed using two different superdisintegrants in varying concentrations in such a way that total weight of the tablet remains the same. The drug-polymer incompatibility was ruled out by FTIR studies. All the formulated tablets were subjected for pre and post-compression evaluation parameters. A comparison of in vitro drug release of best formulation along with F1 formulation having no superdisintegrants is carried out. All the formulated tablets were shown satisfactory results which complies with official limits. Among the seven formulations, F7 was selected as the best formulation as its wetting time was 33 seconds, disintegration time was 29 seconds and %CDR after 8 minutes was 100.1%. F7 was found to be stable at 25°C ± 2 °C,  60°C ± 5°C and 40 °C ± 2 °C and 75 ± 5 % RH . Formulated tablets containing high concentration of croscarmellose sodium are better and effective than conventional tablets to meet patient compliance, give fast relief from allergy and cost effective.

  Rhinitis may be of allergic and non allergic origin and the reaction was typically associated to the nasal and ocular symptoms of the disease, allergic rhinitis was associated with a higher burden of asthma and sinusitis. It also affects multiple areas related to quality of life. Due to these reasons, there is a need to develop rapid action producing formulation to treat these allergic conditions. Levocetrizine is the active enantiomer of cetirizine. It is second generation, non-sedative antihistaminic drug with half-life of 8-10 hrs.The usual dose range from 5 to 10 mg. It undergoes extensive metabolism. The objective of the current study was to develop and optimize fast dissolving tablet of levocetrizine hydrochloride to improve bioavailability and increase drug release with rapid onset action. Key word: Fast dissolving tablet, Superdisintegrant, Rapid action, Patient compliance